Alaven Pharmaceutical Introduces Kit for UC Patients
Posted on: Monday, 9 June 2008, 09:00 CDT
MARIETTA, Ga., June 9 /PRNewswire/ -- When patients with ulcerative colitis (UC) flare, their normal life can be completely disrupted. Bloody diarrhea, frantic urgency and abdominal pain make the bathroom the center of attention.
Alaven Pharmaceutical LLC, a specialty pharmaceutical company focused on developing and commercializing products to treat gastrointestinal conditions, today announced the introduction of a convenience Kit at the American Society of Colon and Rectal Surgeons' annual meeting in Boston. The Kit contains ROWASA(R) (mesalamine) Rectal Suspension Enema 4g/60mL, a treatment for flare symptoms associated with active mild to moderate left-sided UC, proctosigmoiditis, or ulcerative proctitis, and a personal cleansing wipe for added convenience for those inevitable restroom stops.*
"There is a continued need in the marketplace for convenient UC therapy for all patients living with the disease and facing the inevitability of flares," said Connie Swanson, VP, Sales and Marketing at Alaven. "Our hope is that by offering ROWASA in a convenience kit, patients will have access to a soothing topical treatment for more immediate flare relief and that they will be more comfortable with their medication-taking routine."
ROWASA is a prescription medication administered at bedtime for the relief of UC flare symptoms. Applied directly to the site of inflammation, ROWASA reduces rectal bleeding in as little as 3 days(1) and provides fast relief of diarrhea, abdominal pain, and other flare symptoms(2). The full course of treatment with ROWASA (3-6 weeks) is recommended for more complete flare relief(2).
Due to the unpredictable course of UC that is marked by periods of inactivity and then incidences of intermittent flares, patients are at an increased risk for poor adherence to medications. An estimated 34% of patients with left-sided UC have been shown to be non-compliant to prescribed medications(3). Research also shows that innovative ways, including providing convenient medications, may help to motivate patients to adhere(3).
The ROWASA convenience kit helps to improve the delivery and accessibility to reliable UC flare therapy while offering value-added convenience from a personal cleansing wipe that leaves UC patients clean and fresh.*
For additional information, visit http://www.rowasa.com/ . Important Safety Information
Contraindications: ROWASA is contraindicated for patients known to have hypersensitivity to the drug or any component of this medication.
Warning: ROWASA contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but probably low.
Precautions: Mesalamine has been implicated in the production of an acute intolerance syndrome characterized by cramping, acute abdominal pain and bloody diarrhea, sometimes fever, headache and a rash; in such cases prompt withdrawal is required. Caution should be exercised when mesalamine is initially used in patients known to be allergic to sulfasalazine.
Adverse Reactions: ROWASA is usually well tolerated. Most adverse effects have been mild and transient. The most frequently reported adverse events include abdominal cramps, headache, gas, nausea, flu, fatigue, fever and rash.
For Full Prescribing Information - http://www.rowasa.com/ . *Wipe is optional and not a required part of treatment 1 Sutherland LR, et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92(6):1894-1898. 2 ROWASA Prescribing Information. Rev 05/08. 3 Kane SV, et al: The Challenge of Compliance and Persistence: Focus on Ulcerative Colitis. J Manag Care Pharm. 2008;14(1)(suppl S-a):S2-S12. Contact: Rose Raus 404-964-1834 rraus@dodgecommunications.com
Alaven Pharmaceutical LLC
CONTACT: Rose Raus of Alaven Pharmaceutical LLC, +1-404-964-1834,rraus@dodgecommunications.com
Web Site: http://www.rowasa.com/
Source: PRNewswire
Related Articles
- MultiVu Video Feed: FDA Approves DORIBAX(TM) (Doripenem for Injection) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
- FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
- Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) in Patients With Treatment-Resistant Forms of Advanced Leukemias
- Study Showed Treatment With COPAXONE(R) is Associated With Significantly Fewer Days Missed From Work in Multiple Sclerosis Patients; Non-Treatment and Treatment With Avonex(R) or Betaseron(R) Had No Significant Impact on Days Missed
- Study Published in Journal of Clinical Psychiatry Shows Long-Term Treatment- As-Usual Is Ineffective for Patients With Treatment-Resistant Depression
- Two-Year Data Showing Decreases in Suicidality in Patients With Treatment- Resistant Depression Treated With VNS Therapy Presented at Annual American Psychiatric Association Meeting
- FDA Approves New Indication for AVELOX(R) (Moxifloxacin HCl) for Treatment of Complicated Intra-Abdominal Infections (cIAI)
- Savient's Puricase(R) (PEG-Uricase) Substantially Reduces and Sustains Lower Plasma Urate Levels in Patients With Treatment-Resistant Gout
- Patients With Treatment-Resistant Schizophrenia Get Good News Today at American Psychiatric Association Meeting in Atlanta
 |
 |
User Comments (0)
RSS Feeds